Proteomics International Laboratories Ltd. (AU:PIQ)
ASX:PIQ
Want to see AU:PIQ full AI Analyst Report?
PIQ Stock Chart & Stats
AU$0.67
AU$0.03(4.23%)
At close: 4:00 PM EST
AU$0.67
AU$0.03(4.23%)
Day’s Range― - ―
52-Week RangeAU$0.12 - AU$0.86
Previous CloseN/A
Volume90.30K
Average Volume (3M)426.90K
Market Cap
AU$19.82M
Enterprise ValueAU$15.31M
Total Cash (Recent Filing)AU$7.67M
Total Debt (Recent Filing)AU$681.45K
Price to Earnings (P/E)―
Beta1.00
Next Earnings
Sep 01, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.07
Shares Outstanding165,197,510
10 Day Avg. Volume295,611
30 Day Avg. Volume426,904
Financial Highlights & Ratios
PEG Ratio-0.84
Price to Book (P/B)3.69
Price to Sales (P/S)50.61
P/FCF Ratio-7.33
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.04
Revenue Forecast (FY)AU$4.30M
Bulls Say, Bears Say
Bulls Say
Low LeverageMinimal leverage (debt-to-equity 0.021) preserves financial flexibility and lowers fixed interest obligations. For a biotech diagnostics firm, this durable balance-sheet strength reduces bankruptcy risk, supports R&D funding options, and makes future capital raises less pressured over 2–6 months.
Dual Revenue StreamsHaving both diagnostics (per-test revenue) and contract proteomics services diversifies cash flow sources. Services can provide recurring project cash while diagnostics scale, reducing concentration risk and smoothing revenue volatility as clinical adoption and partnerships develop over months.
Positive Gross Margin On PlatformA positive gross margin indicates the core proteomics tests and lab services can be profitable at the cost-of-goods level. This suggests unit economics can support margin expansion if operating expenses are reined in, a durable advantage for long-term commercialization and scalable test rollouts.
Bears Say
Steep Revenue DeclineA very large revenue contraction undermines scale economics and signals weak market adoption, channel issues, or lost contracts. Over the next 2–6 months this materially limits reinvestment capacity, harms bargaining power with partners, and increases execution risk for diagnostic rollouts.
Negative Operating And Free Cash FlowPersistent negative operating and free cash flow indicate the business is burning cash to fund operations. This creates a durable funding pressure, likely necessitating external capital or cost cuts, which can dilute shareholders or slow commercialization and service capacity in the medium term.
Ongoing Losses And Weak MarginsSustained negative EBIT and net margins despite positive gross margin point to high operating expenses relative to revenue. This structural cost base mismatch must be addressed to reach profitability; otherwise, losses will persist and constrain strategic investments and hiring over several quarters.
Proteomics International Laboratories Ltd. News
PIQ FAQ
What was Proteomics International Laboratories Ltd.’s price range in the past 12 months?
Proteomics International Laboratories Ltd. lowest share price was AU$0.12 and its highest was AU$0.86 in the past 12 months.
What is Proteomics International Laboratories Ltd.’s market cap?
Proteomics International Laboratories Ltd.’s market cap is AU$19.82M.
When is Proteomics International Laboratories Ltd.’s upcoming earnings report date?
Proteomics International Laboratories Ltd.’s upcoming earnings report date is Sep 01, 2026 which is in 81 days.
How were Proteomics International Laboratories Ltd.’s earnings last quarter?
Proteomics International Laboratories Ltd. released its earnings results on Feb 25, 2026. The company reported -AU$0.04 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.04.
Is Proteomics International Laboratories Ltd. overvalued?
According to Wall Street analysts Proteomics International Laboratories Ltd.’s price is currently Overvalued.
Does Proteomics International Laboratories Ltd. pay dividends?
Proteomics International Laboratories Ltd. does not currently pay dividends.
What is Proteomics International Laboratories Ltd.’s EPS estimate?
Proteomics International Laboratories Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Proteomics International Laboratories Ltd. have?
Proteomics International Laboratories Ltd. has 165,197,510 shares outstanding.
What happened to Proteomics International Laboratories Ltd.’s price movement after its last earnings report?
Proteomics International Laboratories Ltd. reported an EPS of -AU$0.04 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -2.817%.
Which hedge fund is a major shareholder of Proteomics International Laboratories Ltd.?
Currently, no hedge funds are holding shares in AU:PIQ
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Proteomics International Laboratories Ltd. Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-53.16%
12-Months-Change
Fundamentals
Return on Equity
-93.66%
Trailing 12-Months
Asset Growth
60.94%
Trailing 12-Months
Company Description
Proteomics International Laboratories Ltd.
Proteomics International Laboratories Limited is a medical technology firm deeply engaged in the field of proteomics. Its core offering is PromarkerD, an advanced predictive test for diabetic kidney disease. Additionally, the company is diligently working on developing new diagnostic tools for conditions such as endometriosis and giardia. Beyond its product line, the firm also provides specialized analytical services, particularly focusing on contract research. Proteomics International Laboratories Limited maintains significant research collaborations: it partners with the Busselton Population Medical Research Institute and Janssen Research & Development to explore treatments for diabetic kidney disease, and also collaborates with the QIMR Berghofer Medical Research Institute on initiatives aimed at detecting oesophageal adenocarcinoma. Established in 2001, the company's operations are headquartered in Perth, Australia.
Technical Analysis
Prescient Therapeutics Limited
―
Pharmaust Limited
―
Chimeric Therapeutics Ltd.
―
Radiopharm Theranostics Limited
―
Recce Pharmaceuticals Ltd.
―
Options Prices
Currently, No data available
---